Brief: Savara Announces The U.S. Food & Drug Administration (FDA) Has Extended The Review Period For The Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) In Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune Pap)

Savara

15/04/2026 22:30

April 15 (Reuters) - Savara Inc SVRA.O:

SAVARA ANNOUNCES THE U.S. FOOD & DRUG ADMINISTRATION (FDA) HAS EXTENDED THE REVIEW PERIOD FOR THE MOLGRAMOSTIM INHALATION SOLUTION (MOLGRAMOSTIM) BIOLOGICS LICENSE APPLICATION (BLA) IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (AUTOIMMUNE PAP)

SAVARA INC: PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE EXTENDED BY THREE MONTHS TO NOVEMBER 22, 2026

SAVARA INC - FDA EXTENDS REVIEW PERIOD FOR MOLGRAMOSTIM BLA IN AUTOIMMUNE PAP BY THREE MONTHS

Source text: ID:nBw81N4g3a

Further company coverage: SVRA.O

 ((Reuters.Briefs@thomsonreuters.com;))